Progenra plans to radically change the therapeutic landscape by uncovering first in class, novel therapies from the ubiquitin proteasome system. We have created a knowledge base and patent technology designed to explore the intricacies of the ubiquitin proteasome system and are employing these tools to discover small molecules that modulate the function of key system enzymes for therapeutic benefit. Progenra scientists have discovered small molecule preclinical development candidates for the treatment of cancer (via both classical and immunological mechanisms), inflammatory diseases, and neurodegeneration. An additional outcome of these programs is the identification of small molecule ubiquitin proteasome system modulators, such as the pan-DUB inhibitor PR-619, that have contributed enormously to chemical biology studies of ubiquitin signaling and are employed universally today along with proteasome inhibitors in translational studies. Progenra can provide these assets to any partner with a similar interest; we firmly believe that by combining resources and know-how we can improve a program’s chance of success.
Progenra is seeking industry partnerships for licensing opportunities surrounding the company’s small molecule portfolio, its proprietary UbiPro™ Drug Discovery Platform and its novel PROTAC platform.
- Additionally, the Progenra Discovery Network, established through partnerships with CROs and academic experts, enhances Progenra’s development offerings to industry partners.
- Progenra is focused solely on the ubiquitin proteasome system; with its comprehensive ubiquitin proteasome system tool box, Progenra gives its partners the unique opportunity to progress compounds that will have been thoroughly characterized in vitro and in vivo before they are nominated for preclinical and/or clinical studies.
- The combination of Progenra’s unique technology and expertise provides insight into novel drug targets, affording a strategic timing advantage in partners’ therapeutic areas of interest.
- Please contact Progenra Business Development for enquiries: firstname.lastname@example.org.